Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Summer;18(3):312-326.
doi: 10.30699/IJP.2023.554227.2901. Epub 2023 Jul 16.

The Association Between Higher Expression of Talin-1 and the Reduced Survival Rate in Ovarian Serous Carcinoma Patients

Mina Sharbatoghli  1   2   3 , Leili Saeednejad Zanjani  1   4   3 , Fattahi Fahimeh  1   5 , Elham Kalantari  1 , Zohre Habibi Shams  6 , Mahshid Panahi  6 , Mehdi Totonchi  7   8 , Mohsen Asadi-Lari  1   9 , Zahra Madjd  1   6   10
Affiliations

The Association Between Higher Expression of Talin-1 and the Reduced Survival Rate in Ovarian Serous Carcinoma Patients

Mina Sharbatoghli et al. Iran J Pathol. 2023 Summer.

Abstract

Background & objective: Talin-1 is a constituent of the multiprotein adhesion complexes that play main role in the formation of tumors and migration in different types of malignancies. The present study aimed to assess expression and prognostic significance of the talin-1 protein in ovarian serous carcinoma (OSC) patients.

Methods: The expression of talin-1 in mRNA and its protein levels were investigated for ovarian cancer (OC) by using bioinformatics tools, including Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Gene Expression Database of Normal and Tumor Tissue 2 (GENT2), and The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) databases. Thereafter, immunohistochemical (IHC) staining was used to study the expression patterns of the talin-1 protein using 46 paraffin-embedded OSC tissue specimens, 25 benign tumors, and 20 normal tissues, which were assembled in tissue microarrays (TMAs). We also assessed the potential association between the expression of the talin-1 protein, various clinicopathological parameters, and survival outcomes.

Results: Our IHC examination for talin-1 was significantly overexpressed in OSC tissues compared to benign tumors and normal tissues. The Kaplan-Meier survival analysis has also indicated statistically significant differences in terms of disease-specific survival (DSS) and progression-free survival (PFS) between the patients with high and low expression levels of talin-1, respectively.

Conclusion: The talin-1 protein was overexpressed in OSC tissues, and a high expression level of talin-1 was found to be significantly associated with tumor aggressiveness and poorer DSS or PFS. Therefore, talin-1 may serve as a molecular marker of cancer progression and a novel prognostic biomarker in these patients.

Keywords: Cancer progression; Ovarian serous carcinoma; Prognosis; Talin-1; Tissue microarray.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
The mRNA expression level of Talin-1 in the ovarian serous carcinoma (OSC) using Gene Expression Profiling Interactive Analysis2 (GEPIA2).
Fig. 2
Fig. 2
The mRNA expression level of Talin-1 in the ovarian cancer (OC) using Gene Expression database of Normal and the Tumor tissues 2 (GENT2).
Fig. 3
Fig. 3
Kaplan-Meier survival curves analysis for overall survival (OS) of Talin-1 mRNA expression in the OC patients using bioinformatics tools. A) High Talin-1 expression was found to be associated with a poor prognosis in the OC patients using gene expression database on both normal and the tumor tissues 2 (GENT2) B). The results revealed that OS analysis was not statistically significant using the Gene Expression Profiling Interactive Analysis (GEPIA2) tool.
Fig. 4
Fig. 4
Box plot of the clinical proteomic tumor analysis consortium (CPTAC) results for Talin-1 expression on UALCAN database.
Fig. 5
Fig. 5
Immunohistochemical staining of Talin-1 protein in the ovarian serous carcinoma (OSC) patients, benign tumors, and normal tissues. Low cytoplasmic expression of Talin-1 (A-A-1) and high cytoplasmic Talin-1 expression (B-B-1). Expression of Talin-1 in the benign tumors (C-C-1). Expression of Talin-1 in normal tissues (D). Human normal kidney tissues as controls: positive (E) and negative (F). Isotype control (G). The expression level of Talin-1 was significantly higher in theOSC tissues compared to benign tumors and normal tissue samples. Figures have magnification of 100 × and 200×.
Fig. 6
Fig. 6
Kaplan–Meier curves for disease-specific survival (DSS) and progression-free survival (PFS) according to the expression levels of Talin-1 protein in the ovarian serous carcinoma (OSC) patients. A higher level of Talin-1 protein expression was found to be associated with shorter DSS (A) and PFS (B) compared to the tumors with low Talin-1 protein expression (P=0.026, P= 0.005, respectively).
Fig. 7
Fig. 7
Disease-specific survival (DSS) curves for the patients at (A) FIGO stage I, (B) stage II, and (C) stage III of ovarian serous carcinoma (OSC). The results indicated that high expression of Talin-1 protein is associated with a poorer prognosis in the OSC patients with the advanced disease (FIGO stage III) (P=0.044).
Fig. 8
Fig. 8
Disease-specific survival (DSS) curves for patients in (A) low-grade, (B) high-grade ovarian serous carcinoma (OSC). The results indicated that high level expression of Talin-1 is not significantly related to DSS in the OSC patients in high & low grades.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rock CL, Thomson C, Gansler T, Gapstur SM, McCullough ML, Patel AV, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA Cancer J Clin. 2020;70(4):245–71. - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. - PubMed
    1. Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, et al. Cell Origins of High-Grade Serous Ovarian Cancer. Cancers (Basel). 2018;10:11. - PMC - PubMed
    1. Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, et al. Epithelial ovarian cancer: An overview. World J Transl Med. 2014;3(1):1–8. - PMC - PubMed
    1. Muinao T, Deka Boruah HP, Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon. 2019;5(12):e02826. - PMC - PubMed

LinkOut - more resources